Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.

In an effort to better serve our users, we have streamlined our content offering. As a result, we no longer publish new content or update existing content in Advanced Melanoma. Visit the 'Content & Subscriptions' tab of your Settings page at any time to update your Dashboard or Newsletter Subscription preferences to continue to see news and information that interests you most.

Published in Advanced Melanoma

Journal Scan / Research · February 07, 2023

Efficacy and Safety of HL-085 in Patients With Advanced Melanoma Harboring NRAS Mutations

BMC Medicine


Additional Info

Disclosure statements are available on the authors' profiles:

BMC Medicine
First-in-human phase I dose-escalation and dose-expansion trial of the selective MEK inhibitor HL-085 in patients with advanced melanoma harboring NRAS mutations
BMC Med 2023 Jan 04;21(1)2, X Wang, Z Luo, J Chen, Y Chen, D Ji, L Fan, L Chen, Q Zhao, P Hu, P Sun, Z Jia, J Guo, L Si

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading